{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T06:36:28Z","timestamp":1777358188211,"version":"3.51.4"},"reference-count":161,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy that continues to pose a major clinical challenge, primarily due to the difficulty of early detection and the limited efficacy of existing therapeutic approaches. Immunotherapy, which has revolutionized the treatment of many other cancers, has shown limited success in PDAC, largely because of the complex and immunosuppressive features of its tumor microenvironment (TME). Consequently, strategies aimed at remodeling or modulating the TME have emerged as promising avenues for enhancing the therapeutical potential of immunotherapy in PDAC. MicroRNAs (miRNAs), a class of small non-coding RNAs, have emerged as key regulators of gene expression with multi-target capabilities and relatively low toxicity. Increasing evidence demonstrates that miRNAs play critical roles in regulating immune responses and shaping the TME across diverse tumor types, highlighting their considerable potential in improving immunotherapeutic outcomes in PDAC. In this review, we summarize the functional roles of miRNAs in PDAC and discuss the advantages of miRNA-based therapeutics compared with conventional treatments. We further examine current immunotherapeutic strategies for PDAC and highlight how miRNAs regulate immune activity and TME dynamics, providing mechanistic insights into miRNA-mediated immunotherapy. Finally, we discuss the major challenges limiting clinical translation, including off-target effects, toxicity, and delivery barriers and outline emerging delivery platforms that may enhance therapeutic efficacy. Besides, we explore how emerging technologies, such as artificial intelligence (AI), miniature soft robotics, and advanced 3D imaging ecosystems can be integrated into miRNA-based therapeutic strategies. Together, these innovations may pave the way for more effective, personalized, and patient-centered miRNA-based immunotherapies for PDAC.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1744566","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T05:39:38Z","timestamp":1777354778000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["MicroRNA-based strategies to overcome the immunotherapy barrier in pancreatic ductal adenocarcinoma"],"prefix":"10.3389","volume":"17","author":[{"given":"Huiwen","family":"Xu","sequence":"first","affiliation":[{"name":"School of Pharmacy, Hubei University of Chinese Medicine","place":["Wuhan, China"]},{"name":"Hubei Shizhen Laboratory","place":["Wuhan, China"]},{"name":"Center of Traditional Chinese Medicine Modernization for Liver Diseases, Hubei University of Chinese Medicine","place":["Wuhan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Hubei University of Chinese Medicine","place":["Wuhan, China"]},{"name":"Hubei Shizhen Laboratory","place":["Wuhan, China"]},{"name":"Center of Traditional Chinese Medicine Modernization for Liver Diseases, Hubei University of Chinese Medicine","place":["Wuhan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rubin","family":"Cao","sequence":"additional","affiliation":[{"name":"Wuhan Jiulong Pharmaceutical Co. Ltd","place":["Wuhan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenpeng","family":"Qiu","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Hubei University of Chinese Medicine","place":["Wuhan, China"]},{"name":"Hubei Shizhen Laboratory","place":["Wuhan, China"]},{"name":"Center of Traditional Chinese Medicine Modernization for Liver Diseases, Hubei University of Chinese Medicine","place":["Wuhan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhui","family":"Liu","sequence":"additional","affiliation":[{"name":"Division of Hepato-Pancreato-Biliary Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology","place":["Wuhan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junjie","family":"Hu","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Hubei University of Chinese Medicine","place":["Wuhan, China"]},{"name":"Hubei Shizhen Laboratory","place":["Wuhan, China"]},{"name":"Center of Traditional Chinese Medicine Modernization for Liver Diseases, Hubei University of Chinese Medicine","place":["Wuhan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guohua","family":"Zheng","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Hubei University of Chinese Medicine","place":["Wuhan, China"]},{"name":"Hubei Shizhen Laboratory","place":["Wuhan, China"]},{"name":"Center of Traditional Chinese Medicine Modernization for Liver Diseases, Hubei University of Chinese Medicine","place":["Wuhan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Cheng","sequence":"additional","affiliation":[{"name":"Hubei Shizhen Laboratory","place":["Wuhan, China"]},{"name":"Center of Traditional Chinese Medicine Modernization for Liver Diseases, Hubei University of Chinese Medicine","place":["Wuhan, China"]},{"name":"Key Laboratory of Chinese Medicine Resource and Compound Prescription, Ministry of Education, Hubei University of Chinese Medicine","place":["Wuhan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)30974-0","article-title":"Pancreatic cancer","volume":"395","author":"Mizrahi","year":"2020","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jncc.2024.01.006","article-title":"Cancer incidence and mortality in China, 2022","volume":"4","author":"Han","year":"2024","journal-title":"J Natl Cancer Cent"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.13027","article-title":"Pancreatic cancer: a review","volume":"326","author":"Park","year":"2021","journal-title":"Jama"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-20-2256","article-title":"Light at night and risk of pancreatic cancer in the NIH-AARP diet and health study","volume":"81","author":"Xiao","year":"2021","journal-title":"Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.02.014","article-title":"Pancreatic cancer: advances and challenges","volume":"186","author":"Halbrook","year":"2023","journal-title":"Cell"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-19-0094","article-title":"Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts","volume":"9","author":"Elyada","year":"2019","journal-title":"Cancer Discov"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02605-9","article-title":"Systemic but not MDSC-specific IRF4 deficiency promotes an immunosuppressed tumor microenvironment in a murine pancreatic cancer model","volume":"69","author":"Metzger","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B10","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1186\/s40425-019-0778-7","article-title":"Immunostimulatory RNA leads to functional reprogramming of myeloid-derived suppressor cells in pancreatic cancer","volume":"7","author":"Metzger","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2014.04.005","article-title":"Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival","volume":"25","author":"\u00d6zdemir","year":"2014","journal-title":"Cancer Cell"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2012.01.007","article-title":"Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma","volume":"21","author":"Provenzano","year":"2012","journal-title":"Cancer Cell"},{"key":"B13","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s00262-024-03632-6","article-title":"Clinical immunotherapy in pancreatic cancer","volume":"73","author":"Ye","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70162","article-title":"Pancreatic cancer: pathogenesis and clinical studies","volume":"6","author":"Zhou","year":"2025","journal-title":"Medcomm (2020)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1621\/datasets.04001","article-title":"The PARP superfamily","volume":"26","author":"Am\u00e9","year":"2004","journal-title":"Bioessays"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.02233","article-title":"Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial","volume":"40","author":"Versteijne","year":"2022","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(24)00511-4","article-title":"Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: a systematic review and Bayesian network meta-analysis","volume":"25","author":"Mastrantoni","year":"2024","journal-title":"Lancet Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)01366-1","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-17-2994","article-title":"Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial","volume":"24","author":"Aung","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3724","article-title":"GATA6 expression distinguishes classical and basal-like subtypes in advanced pancreatic cancer","volume":"26","author":"O'Kane","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14010236","article-title":"BRCA 1\/2 germline mutation predicts the treatment response of FOLFIRINOX with pancreatic ductal adenocarcinoma in Korean patients","volume":"14","author":"Park","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/po.17.00152","article-title":"Retrospective survival analysis of patients with advanced pancreatic ductal adenocarcinoma and germline BRCA or PALB2 mutations","volume":"2","author":"Reiss","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.39.5590","article-title":"Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study","volume":"30","author":"Win","year":"2012","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1126\/science.1171202","article-title":"Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene","volume":"324","author":"Jones","year":"2009","journal-title":"Science"},{"key":"B26","article-title":"Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations","volume":"60","author":"Lal","year":"2000","journal-title":"Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2012.12.018","article-title":"Cancer risk associated with STK11\/LKB1 germline mutations in Peutz-Jeghers syndrome patients: results of an Italian multicenter study","volume":"45","author":"Resta","year":"2013","journal-title":"Dig Liver Dis"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-11-0194","article-title":"ATM mutations in patients with hereditary pancreatic cancer","volume":"2","author":"Roberts","year":"2012","journal-title":"Cancer Discov"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-018-2666-9","article-title":"Emerging strategies in BRCA-positive pancreatic cancer","volume":"144","author":"Kowalewski","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw327","article-title":"Prevention and screening in BRCA mutation carriers and other breast\/ovarian hereditary cancer syndromes: ESMO clinical practice guidelines for cancer prevention and screening","volume":"27","author":"Paluch-Shimon","year":"2016","journal-title":"Ann Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2015.10.013","article-title":"PARP-1 activation requires local unfolding of an autoinhibitory domain","volume":"60","author":"Dawicki-McKenna","year":"2015","journal-title":"Mol Cell"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"B33","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/bcr2877","article-title":"Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer","volume":"13","author":"Plummer","year":"2011","journal-title":"Breast Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/med.21339","article-title":"Deciphering the insights of poly(ADP-ribosylation) in tumor progression","volume":"35","author":"Rodr\u00edguez","year":"2015","journal-title":"Med Res Rev"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2147\/ott.s139336","article-title":"Current status of poly(ADP-ribose) polymerase inhibitors and future directions","volume":"10","author":"Ohmoto","year":"2017","journal-title":"Onco Targets Ther"},{"key":"B36","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12943-020-01167-9","article-title":"PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications","volume":"19","author":"Zhu","year":"2020","journal-title":"Mol Cancer"},{"key":"B37","article-title":"Nuclear translocation of the receptor tyrosine kinase c-MET reduces the treatment efficacies of olaparib and gemcitabine in pancreatic ductal adenocarcinoma cells","volume":"11","author":"Gao","year":"2021","journal-title":"Am J Cancer Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.05.035","article-title":"The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors","volume":"44","author":"Miller","year":"2019","journal-title":"EBioMedicine"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23042268","article-title":"VPA and TSA interrupt the interplay between mutp53 and HSP70, leading to CHK1 and RAD51 down-regulation and sensitizing pancreatic cancer cells to AZD2461 PARP inhibitor","volume":"23","author":"Romeo","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-20-0163","article-title":"Phase I trial of the PARP inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1\/2- and non-BRCA1\/2-mutant cancers","volume":"10","author":"Yap","year":"2020","journal-title":"Cancer Discov"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.95","article-title":"Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pancreatic cancer","volume":"116","author":"Hurt","year":"2017","journal-title":"Br J Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2003.11.003","article-title":"Intensity-modulated radiotherapy in treatment of pancreatic and bile duct Malignancies: toxicity and clinical outcome","volume":"59","author":"Milano","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.10.043","article-title":"Intensity-modulated radiation therapy significantly improves acute gastrointestinal toxicity in pancreatic and ampullary cancers","volume":"79","author":"Yovino","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2016.10.030","article-title":"Stereotactic body radiation therapy for locally advanced pancreatic cancer: a systematic review and pooled analysis of 19 trials","volume":"97","author":"Petrelli","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2020.11.006","article-title":"A phase II study of stereotactic radiotherapy after FOLFIRINOX for locally advanced pancreatic cancer (LAPC-1 trial): long-term outcome","volume":"155","author":"Teriaca","year":"2021","journal-title":"Radiother Oncol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"100506","DOI":"10.1016\/j.adro.2020.06.010","article-title":"Ablative five-fraction stereotactic body radiation therapy for inoperable pancreatic cancer using online MR-guided adaptation","volume":"6","author":"Hassanzadeh","year":"2021","journal-title":"Adv Radiat Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2100","article-title":"Using adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer","volume":"8","author":"Rudra","year":"2019","journal-title":"Cancer Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"63","DOI":"10.7150\/ijbs.101861","article-title":"Targeting protein modification: a new direction for immunotherapy of pancreatic cancer","volume":"21","author":"Ge","year":"2025","journal-title":"Int J Biol Sci"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1588","article-title":"Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial","volume":"5","author":"O'Reilly","year":"2019","journal-title":"JAMA Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1097\/cji.0b013e3181eec14c","article-title":"Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma","volume":"33","author":"Royal","year":"2010","journal-title":"J Immunother"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01800-8","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results","volume":"28","author":"Qi","year":"2022","journal-title":"Nat Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt066","article-title":"Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer","volume":"24","author":"Wolpin","year":"2013","journal-title":"Ann Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003050","article-title":"Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors","volume":"9","author":"Jan","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B55","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1056\/NEJMoa2119662","article-title":"Neoantigen T-cell receptor gene therapy in pancreatic cancer","volume":"387","author":"Simnica","year":"2022","journal-title":"N Engl J Med"},{"key":"B56","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.pan.2025.07.387","article-title":"Chimeric antigen receptor macrophages targeting c-MET(CAR-M-c-MET) inhibit pancreatic cancer progression and improve cytotoxic chemotherapeutic efficacy","volume":"23","author":"Zheng","year":"2024","journal-title":"Mol Cancer"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"B58","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/s41392-024-02031-8","article-title":"Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally advanced or metastatic pancreatic ductal adenocarcinoma: a phase Ib\/II trial","volume":"9","author":"Cheng","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.02616","article-title":"Immunologic strategies in pancreatic cancer: making cold tumors hot","volume":"40","author":"Ullman","year":"2022","journal-title":"J Clin Oncol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.addr.2014.10.020","article-title":"Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer","volume":"81","author":"Rachagani","year":"2015","journal-title":"Adv Drug Delivery Rev"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.640587","article-title":"MicroRNA-34a: potent tumor suppressor, cancer stem cell inhibitor, and potential anticancer therapeutic","volume":"9","author":"Li","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.2174\/1566524011313040001","article-title":"MicroRNA-34b inhibits pancreatic cancer metastasis through repressing Smad3","volume":"13","author":"Liu","year":"2013","journal-title":"Curr Mol Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13144","article-title":"MicroRNA-based targeted therapeutics in pancreatic cancer","volume":"39","author":"Gurbuz","year":"2019","journal-title":"Anticancer Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.2147\/cmar.s387344","article-title":"miR-455-3p functions as a tumor suppressor by restraining wnt\/\u03b2-catenin signaling via TAZ in pancreatic cancer","volume":"12","author":"Zhan","year":"2020","journal-title":"Cancer Manag Res"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2019.11.010","article-title":"Functional significance and therapeutic potential of miR-15a mimic in pancreatic ductal adenocarcinoma","volume":"19","author":"Guo","year":"2020","journal-title":"Mol Ther Nucleic Acids"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.pan.2012.02.008","article-title":"miR-15b and miR-16 induce the apoptosis of rat activated pancreatic stellate cells by targeting Bcl-2 in vitro","volume":"12","author":"Shen","year":"2012","journal-title":"Pancreatology"},{"key":"B67","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.semcancer.2017.11.020","article-title":"MicroRNA regulation of K-Ras in pancreatic cancer and opportunities for therapeutic intervention","volume":"54","author":"Karmakar","year":"2019","journal-title":"Semin Cancer Biol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1101\/gad.1950610","article-title":"Repression of the miR-143\/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway","volume":"24","author":"Kent","year":"2010","journal-title":"Genes Dev"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2017.05.007","article-title":"Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205","volume":"402","author":"Chaudhary","year":"2017","journal-title":"Cancer Lett"},{"key":"B70","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ajpath.2018.10.005","article-title":"miRNA and gene expression in pancreatic ductal adenocarcinoma","volume":"189","author":"Tesfaye","year":"2019","journal-title":"Am J Pathol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgr223","article-title":"MicroRNA-150 directly targets MUC4 and suppresses growth and Malignant behavior of pancreatic cancer cells","volume":"32","author":"Srivastava","year":"2011","journal-title":"Carcinogenesis"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-016-0407-y","article-title":"Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors","volume":"35","author":"Beg","year":"2017","journal-title":"Invest New Drugs"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242417523","article-title":"Functional and potential therapeutic implication of microRNAs in pancreatic cancer","volume":"24","author":"Pal","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2013.05.049","article-title":"Silencing of miR-21 by locked nucleic acid-lipid nanocapsule complexes sensitize human glioblastoma cells to radiation-induced cell death","volume":"454","author":"Griveau","year":"2013","journal-title":"Int J Pharm"},{"key":"B75","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1038\/s41419-020-02855-6","article-title":"MiR-93 suppresses tumorigenesis and enhances chemosensitivity of breast cancer via dual targeting E2F1 and CCND1","volume":"11","author":"Bao","year":"2020","journal-title":"Cell Death Dis"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-024-16115-w","article-title":"miR-6855-5p Enhances Radioresistance and Promotes Migration of Pancreatic Cancer by Inducing Epithelial-Mesenchymal Transition via Suppressing FOXA1: Potential of Plasma Exosomal miR-6855-5p as an Indicator of Radiosensitivity in Patients with Pancreatic Cancer","volume":"32","author":"Ueda","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12943-022-01587-9","article-title":"Hsa-miR-3178\/RhoB\/PI3K\/Akt, a novel signaling pathway regulates ABC transporters to reverse gemcitabine resistance in pancreatic cancer","volume":"21","author":"Gu","year":"2022","journal-title":"Mol Cancer"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.07.048","article-title":"MicroRNA 23b regulates autophagy associated with radioresistance of pancreatic cancer cells","volume":"145","author":"Wang","year":"2013","journal-title":"Gastroenterology"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-021-04289-z","article-title":"MiRNA-3662 reverses the gemcitabine resistance in pancreatic cancer through regulating the tumor metabolism","volume":"88","author":"Liu","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.21037\/atm-21-6556","article-title":"MiR-499a-5p promotes 5-FU resistance and the cell proliferation and migration through activating PI3K\/Akt signaling by targeting PTEN in pancreatic cancer","volume":"9","author":"Ouyang","year":"2021","journal-title":"Ann Transl Med"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11041136","article-title":"Anti-microRNA-1976 as a novel approach to enhance chemosensitivity in XAF1(+) pancreatic and liver cancer","volume":"11","author":"Lee","year":"2023","journal-title":"Biomedicines"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12488","article-title":"Extracellular vesicles miR-31-5p promotes pancreatic cancer chemoresistance via regulating LATS2-Hippo pathway and promoting SPARC secretion from pancreatic stellate cells","volume":"13","author":"Qin","year":"2024","journal-title":"J Extracell Vesicles"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3892\/or.2015.4078","article-title":"MicroRNA-216a enhances the radiosensitivity of pancreatic cancer cells by inhibiting beclin-1-mediated autophagy","volume":"34","author":"Zhang","year":"2015","journal-title":"Oncol Rep"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3390\/cells11152294","article-title":"The influence of microRNA-31 on oxidative stress and radiosensitivity in pancreatic ductal adenocarcinoma","volume":"11","author":"McGrath","year":"2022","journal-title":"Cells"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3892\/or.2016.5122","article-title":"MicroRNA miR-374, a potential radiosensitizer for carbon ion beam radiotherapy","volume":"36","author":"Baek","year":"2016","journal-title":"Oncol Rep"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1097\/mpa.0000000000000640","article-title":"miR-216b targets FGFR1 and confers sensitivity to radiotherapy in pancreatic ductal adenocarcinoma patients without EGFR or KRAS mutation","volume":"45","author":"Egeli","year":"2016","journal-title":"Pancreas"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4210","article-title":"miR-620 promotes tumor radioresistance by targeting 15-hydroxyprostaglandin dehydrogenase (HPGD)","volume":"6","author":"Huang","year":"2015","journal-title":"Oncotarget"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e31346","article-title":"Pancreatic cancer cells hijack tumor suppressive microRNA-26a to promote radioresistance and potentiate tumor repopulation","volume":"10","author":"Jiang","year":"2024","journal-title":"Heliyon"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-12-81","article-title":"miR-99b-targeted mTOR induction contributes to irradiation resistance in pancreatic cancer","volume":"12","author":"Wei","year":"2013","journal-title":"Mol Cancer"},{"key":"B90","doi-asserted-by":"publisher","first-page":"216873","DOI":"10.2139\/ssrn.4630692","article-title":"RAS-RAF-miR-296-3p signaling axis increases Rad18 expression to augment radioresistance in pancreatic and thyroid cancers","volume":"591","author":"Wolfe","year":"2024","journal-title":"Cancer Lett"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23063231","article-title":"Interactions between miRNAs and double-strand breaks DNA repair genes, pursuing a fine-tuning of repair","volume":"23","author":"Peraza-Vega","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.4161\/auto.27418","article-title":"MIR34A regulates autophagy and apoptosis by targeting HMGB1 in the retinoblastoma cell","volume":"10","author":"Liu","year":"2014","journal-title":"Autophagy"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2015.12.046","article-title":"Platinum and PARP inhibitor resistance due to overexpression of microRNA-622 in BRCA1-mutant ovarian cancer","volume":"14","author":"Choi","year":"2016","journal-title":"Cell Rep"},{"key":"B94","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s13578-023-01151-y","article-title":"MiR-181a targets STING to drive PARP inhibitor resistance in BRCA- mutated triple-negative breast cancer and ovarian cancer","volume":"13","author":"Bustos","year":"2023","journal-title":"Cell Biosci"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2017.11.016","article-title":"Oncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNA","volume":"47","author":"Coelho","year":"2017","journal-title":"Immunity"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2012.04.025","article-title":"Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer","volume":"21","author":"Bayne","year":"2012","journal-title":"Cancer Cell"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2014.03.014","article-title":"Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia","volume":"25","author":"McAllister","year":"2014","journal-title":"Cancer Cell"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104250","article-title":"Deciphering the role of KRAS gene in oncogenesis: Focus on signaling pathways, genetic alterations in 3'UTR, KRAS specific miRNAs and therapeutic interventions","volume":"194","author":"Chhichholiya","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6770","article-title":"The prognostic role of desmoplastic stroma in pancreatic ductal adenocarcinoma","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4123","article-title":"Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy","volume":"22","author":"Jiang","year":"2016","journal-title":"Nat Med"},{"key":"B101","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/s41420-024-02146-5","article-title":"The role of cancer-associated fibroblasts and exosomal miRNAs-mediated intercellular communication in the tumor microenvironment and the biology of carcinogenesis: a systematic review","volume":"10","author":"Nedaeinia","year":"2024","journal-title":"Cell Death Discov"},{"key":"B102","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41392-024-01872-7","article-title":"Engineered extracellular vesicles for targeted reprogramming of cancer-associated fibroblasts to potentiate therapy of pancreatic cancer","volume":"9","author":"Zhou","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2023.100960","article-title":"Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs","volume":"68","author":"Qi","year":"2023","journal-title":"Drug Resist Update"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.06.030","article-title":"MicroRNA 125a regulates MHC-I expression on esophageal adenocarcinoma cells, associated with suppression of antitumor immune response and poor outcomes of patients","volume":"155","author":"Mari","year":"2018","journal-title":"Gastroenterology"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241512459","article-title":"BRAF, TERT and HLA-G status in the papillary thyroid carcinoma: A clinicopathological association study","volume":"24","author":"Bertol","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.12.038","article-title":"Broadening the impact of immunotherapy to pancreatic cancer: Challenges and opportunities","volume":"156","author":"Balachandran","year":"2019","journal-title":"Gastroenterology"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1172\/jci59227","article-title":"Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice","volume":"122","author":"Collins","year":"2012","journal-title":"J Clin Invest"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2013-306271","article-title":"Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity","volume":"63","author":"Stromnes","year":"2014","journal-title":"Gut"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-313738","article-title":"Targeting both tumour-associated CXCR2(+) neutrophils and CCR2(+) macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma","volume":"67","author":"Nywening","year":"2018","journal-title":"Gut"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1160181","article-title":"MiRNA dynamics in tumor-infiltrating myeloid cells modulating tumor progression in pancreatic cancer","volume":"5","author":"M\u00fchlberg","year":"2016","journal-title":"Oncoimmunology"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-18-0124","article-title":"Transfer of miRNA in macrophage-derived exosomes induces drug resistance in pancreatic adenocarcinoma","volume":"78","author":"Binenbaum","year":"2018","journal-title":"Cancer Res"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2024.2424490","article-title":"Extracellular vesicle-packaged miR-4253 secreted by cancer-associated fibroblasts facilitates cell proliferation in gastric cancer by inducing macrophage M2 polarization","volume":"25","author":"Duan","year":"2024","journal-title":"Cancer Biol Ther"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.111407","article-title":"Pancreatic cancer stem cell-derived exosomal miR-210 mediates macrophage M2 polarization and promotes gemcitabine resistance by targeting FGFRL1","volume":"127","author":"Guo","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00890","article-title":"MiR-128 regulates tumor cell CD47 expression and promotes anti-tumor immunity in pancreatic cancer","volume":"11","author":"Xi","year":"2020","journal-title":"Front Immunol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1186\/s12967-024-05963-5","article-title":"Unraveling the interplay of CD8\u2009+\u2009T cells and microRNA signaling in cancer: Implications for immune dysfunction and therapeutic approaches","volume":"22","author":"Zabeti Touchaei","year":"2024","journal-title":"J Transl Med"},{"key":"B116","doi-asserted-by":"publisher","first-page":"5585","DOI":"10.1038\/s41467-023-40959-7","article-title":"Let-7 enhances murine anti-tumor CD8 T cell responses by promoting memory and antagonizing terminal differentiation","volume":"14","author":"Wells","year":"2023","journal-title":"Nat Commun"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2017.6566","article-title":"MicroRNA-452 suppresses pancreatic cancer migration and invasion by directly targeting B-cell-specific Moloney murine leukemia virus insertion site 1","volume":"14","author":"Li","year":"2017","journal-title":"Oncol Lett"},{"key":"B118","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1186\/s13046-024-03240-3","article-title":"Inhibition of the chemokine receptors CXCR1 and CXCR2 synergizes with docetaxel for effective tumor control and remodeling of the immune microenvironment of HPV-negative head and neck cancer models","volume":"43","author":"Horn","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.13546","article-title":"Th17 cells target the metabolic miR-142-5p-succinate dehydrogenase subunit C\/D (SDHC\/SDHD) axis, promoting invasiveness and progression of cervical cancers","volume":"18","author":"Pohlers","year":"2024","journal-title":"Mol Oncol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009774","article-title":"Immune modulatory microRNAs in tumors, their clinical relevance in diagnosis and therapy","volume":"12","author":"Vaxevanis","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2022.03.010","article-title":"MiR-15a and miR-15b modulate natural killer and CD8(+)T-cell activation and anti-tumor immune response by targeting PD-L1 in neuroblastoma","volume":"25","author":"Pathania","year":"2022","journal-title":"Mol Ther Oncolytics"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.720125","article-title":"Identification of the prognosis value and potential mechanism of immune checkpoints in renal clear cell carcinoma microenvironment","volume":"11","author":"Liao","year":"2021","journal-title":"Front Oncol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2019.11234","article-title":"MicroRNA-519 inhibits hypoxia-induced tumorigenesis of pancreatic cancer by regulating immune checkpoint PD-L1","volume":"19","author":"Nong","year":"2020","journal-title":"Oncol Lett"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107822","article-title":"MiR-194-5p down-regulates tumor cell PD-L1 expression and promotes anti-tumor immunity in pancreatic cancer","volume":"97","author":"Wang","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.mcr-18-0831","article-title":"MiRNA-148a-3p regulates immunosuppression in DNA mismatch repair-deficient colorectal cancer by targeting PD-L1","volume":"17","author":"Ashizawa","year":"2019","journal-title":"Mol Cancer Res"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-22-2155","article-title":"RNA therapeutics for improving CAR T-cell safety and efficacy","volume":"83","author":"Schaible","year":"2023","journal-title":"Cancer Res"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2019.12.008","article-title":"MiR-155 overexpression in OT-1 CD8(+) T cells improves anti-tumor activity against low-affinity tumor antigen","volume":"16","author":"Monnot","year":"2020","journal-title":"Mol Ther Oncolytics"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1186\/2051-1426-1-21","article-title":"Expression of miR-17\u201392 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts","volume":"1","author":"Ohno","year":"2013","journal-title":"J Immunother Cancer"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1422916112","article-title":"MiR-155 augments CD8+ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic \u03b3c cytokines","volume":"112","author":"Ji","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2016.03.012","article-title":"MicroRNA-30c promotes natural killer cell cytotoxicity via up-regulating the expression level of NKG2D","volume":"151","author":"Ma","year":"2016","journal-title":"Life Sci"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-023-00530-4","article-title":"Novel role of immune-related non-coding RNAs as potential biomarkers regulating tumour immunoresponse via MICA\/NKG2D pathway","volume":"11","author":"Zhang","year":"2023","journal-title":"biomark Res"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2287","article-title":"MicroRNA-mediated down-regulation of NKG2D ligands contributes to glioma immune escape","volume":"5","author":"Codo","year":"2014","journal-title":"Oncotarget"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-0802-1","article-title":"Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours","volume":"122","author":"Hong","year":"2020","journal-title":"Br J Cancer"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1586\/era.11.184","article-title":"MicroRNAs as markers of survival and chemoresistance in pancreatic ductal adenocarcinoma","volume":"11","author":"Frampton","year":"2011","journal-title":"Expert Rev Anticancer Ther"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2013.405","article-title":"MicroRNA-10b enhances pancreatic cancer cell invasion by suppressing TIP30 expression and promoting EGF and TGF-\u03b2 actions","volume":"33","author":"Ouyang","year":"2014","journal-title":"Oncogene"},{"key":"B136","doi-asserted-by":"publisher","first-page":"548\u2013","DOI":"10.1158\/1538-7445.am2023-548","article-title":"Abstract 548: The microRNA-10b targeted therapeutic, TTX-MC138, is effective in preclinical pancreatic adenocarcinoma","volume":"83","author":"Ghosh","year":"2023","journal-title":"Cancer Res"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1642","article-title":"Human microRNAs regulate stress-induced immune responses mediated by the receptor NKG2D","volume":"9","author":"Stern-Ginossar","year":"2008","journal-title":"Nat Immunol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v27.i24.3568","article-title":"Room for improvement in the treatment of pancreatic cancer: Novel opportunities from gene targeted therapy","volume":"27","author":"Galanopoulos","year":"2021","journal-title":"World J Gastroenterol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13267","article-title":"Co-delivery of microRNA-21 antisense oligonucleotides and gemcitabine using nanomedicine for pancreatic cancer therapy","volume":"108","author":"Li","year":"2017","journal-title":"Cancer Sci"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1002\/bab.2701","article-title":"Ionizable cationic lipid nanoparticles loaded with miRNA-125b\/BLZ945 for pancreatic cancer treatment","volume":"72","author":"Zhang","year":"2025","journal-title":"Biotechnol Appl Biochem"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abd6764","article-title":"Redox-responsive nanoplatform for codelivery of miR-519c and gemcitabine for pancreatic cancer therapy","volume":"6","author":"Xin","year":"2020","journal-title":"Sci Adv"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.2147\/dddt.s265423","article-title":"Exosomes-coated miR-34a displays potent antitumor activity in pancreatic cancer both in vitro and in vivo","volume":"14","author":"Zuo","year":"2020","journal-title":"Drug Des Devel Ther"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2633","article-title":"Exosomal miRNA-1231 derived from bone marrow mesenchymal stem cells inhibits the activity of pancreatic cancer","volume":"8","author":"Shang","year":"2019","journal-title":"Cancer Med"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2016-100774","article-title":"Therapeutic endoscopic ultrasound","volume":"8","author":"Venkatachalapathy","year":"2017","journal-title":"Frontline Gastroenterol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4183","article-title":"RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients","volume":"6","author":"Golan","year":"2015","journal-title":"Oncotarget"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1007\/s00534-011-0457-7","article-title":"Phase I trial of preoperative intratumoral injection of immature dendritic cells and OK-432 for resectable pancreatic cancer patients","volume":"19","author":"Endo","year":"2012","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1016\/j.gie.2017.10.030","article-title":"Effects of EUS-guided intratumoral injection of oligonucleotide STNM01 on tumor growth, histology, and overall survival in patients with unresectable pancreatic cancer","volume":"87","author":"Nishimura","year":"2018","journal-title":"Gastrointest Endosc"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1016\/j.gie.2016.11.014","article-title":"EUS-guided fine-needle injection of gemcitabine for locally advanced and metastatic pancreatic cancer","volume":"86","author":"Levy","year":"2017","journal-title":"Gastrointest Endosc"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1016\/s0016-5107(05)01454-9","article-title":"Endoscopic ultrasound-guided fine-needle injection of immature dendritic cells into advanced pancreatic cancer refractory to gemcitabine: a pilot study","volume":"35","author":"Irisawa","year":"2007","journal-title":"Pancreas"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1097\/mpa.0b013e318197a9e3","article-title":"A combination therapy of gemcitabine with immunotherapy for patients with inoperable locally advanced pancreatic cancer","volume":"38","author":"Hirooka","year":"2009","journal-title":"Pancreas"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2024.07.023","article-title":"Enhancing pancreatic cancer immunotherapy: Leveraging localized delivery strategies through the use of implantable devices and scaffolds","volume":"373","author":"Minaei","year":"2024","journal-title":"J Control Release"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202411494","article-title":"Deeply implantable, shape-morphing, 3D microLEDs for pancreatic cancer therapy","volume":"37","author":"Lee","year":"2025","journal-title":"Adv Mater"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114308","article-title":"Local scaffold-assisted delivery of immunotherapeutic agents for improved cancer immunotherapy","volume":"185","author":"Shang","year":"2022","journal-title":"Adv Drug Delivery Rev"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2017.07.021","article-title":"Drug-eluting scaffold inhibited in vivo pancreatic tumorigenesis by engaging murine CCR4(+)CD8(+) T cells","volume":"158","author":"Zhan","year":"2017","journal-title":"Colloids Surf B Biointerfaces"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202206873","article-title":"Sustained intratumoral administration of agonist CD40 antibody overcomes immunosuppressive tumor microenvironment in pancreatic cancer","volume":"10","author":"Liu","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"B156","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.annonc.2023.10.125","article-title":"Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review","volume":"35","author":"Prelaj","year":"2024","journal-title":"Ann Oncol"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217350","article-title":"Frontiers in pancreatic cancer on biomarkers, microenvironment, and immunotherapy","volume":"610","author":"Yu","year":"2025","journal-title":"Cancer Lett"},{"key":"B158","doi-asserted-by":"publisher","first-page":"16393","DOI":"10.1038\/s41598-022-20783-7","article-title":"Panels of mRNAs and miRNAs for decoding molecular mechanisms of Renal Cell Carcinoma (RCC) subtypes utilizing artificial intelligence approaches","volume":"12","author":"Hosseiniyan Khatibi","year":"2022","journal-title":"Sci Rep"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1244578","article-title":"Proposing new early detection indicators for pancreatic cancer: combining machine learning and neural networks for serum miRNA-based diagnostic model","volume":"13","author":"Chi","year":"2023","journal-title":"Front Oncol"},{"key":"B160","doi-asserted-by":"publisher","first-page":"10138","DOI":"10.1038\/s41467-024-54267-1","article-title":"LungVis 1.0: an automatic AI-powered 3D imaging ecosystem unveils spatial profiling of nanoparticle delivery and acinar migration of lung macrophages","volume":"15","author":"Yang","year":"2024","journal-title":"Nat Commun"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202408750","article-title":"Magnetic miniature soft robot with reprogrammable drug-dispensing functionalities: toward advanced targeted combination therapy","volume":"36","author":"Yang","year":"2024","journal-title":"Adv Mater"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1744566\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T05:39:40Z","timestamp":1777354780000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1744566\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":161,"alternative-id":["10.3389\/fimmu.2026.1744566"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1744566","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"article-number":"1744566"}}